Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system. By combining longitudinal MRI-based brain morphometry and brain age estimation using machine learning, we tested the hypothesis that MS patients have higher brain age relative to chronological age than healthy controls (HC) and that longitudinal rate of brain aging in MS patients is associated with clinical course.
INTRODUCTION
Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system (CNS). The prevalence of MS varies across the world and has been reported above 200/100.000 in some European countries 1 . The disease affects women more frequently than men 2 . The complex pathophysiology of MS can be divided into acute inflammation during a relapse and chronic inflammation thought to continuously disturb neuroaxonal homeostasis and drive neurodegeneration 3 .
After the initial diagnosis, which is usually established in early adulthood, patients experience different disease activity and longitudinal accumulation of neurological damage.
Development of robust brain imaging markers that can parse this between-subject heterogeneity of the clinical trajectories, predict future progression of disability, and monitor the effects of treatment is a major aim with important clinical implications 4 5 . Current imaging markers with relevance for MS are associated with disease activity and progression, and include, among other features, number or volume of hyperintense brain lesions visible on T2-weighted MRI images, contrast-enhancing T1 lesions, increased annual brain volume loss and T1-hypointense "black holes" 4 6 7 . Increased rate of brain volume loss, which is best captured using longitudinal designs 8 , reflects accelerated neurodegeneration 9 . Tuning the analysis towards specific brain regions may boost the correlations between estimated brain atrophy and disability 4 . However, identifying robust associations between clinical outcomes and MRI measures has been challenging 10 . This clinico-radiological paradox in MS is likely explained by a combination of lack of sensitivity and specificity both in the clinical and imaging domain. Indeed, expanded disability status scale (EDSS) and relapse rate, which are frequently used as clinical measures in MS phase III trials, are not sensitive to the full clinical spectrum in MS 11 12 . Ongoing efforts are made to develop and validate novel multidimensional measures to capture subtle changes in MS activity and progression 12 . The concept of "No evidence of disease activity" (NEDA) has emerged in the last decade as one such promising multidimensional measure of MS disease activity 13 . On the imaging side, recent technological advances for improved acquisition and analyses are likely to overcome some of the current challenges related to brain scan reproducibility and across-site harmonization and contribute towards a predictive MRI marker for disability and the effect of treatment in patients with MS in a clinical setting 4 .
Essentially, brain age estimation uses machine learning on a large training set of MRI data from healthy controls (HC) to develop a model that can accurately predict the individual age from brain imaging data [14] [15] [16] . Utilizing sensitive measures of MRI-based brain morphometry, brain age estimation provides a robust imaging-based biomarker with potential to yield novel insights into similarities and differences of disease pathophysiology across brain disorders 15 17 . Such imaging-based brain age has been shown to be reliable both within and between MRI scanners, and is a candidate biomarker of an individual's brain health and integrity 14 15 17 . Different approaches to brain age estimation utilize information from a variety of brain regions (e.g. hippocampus, subcortical, grey matter and white matter 18 ) or MRI sequences (e.g. T1, T2, diffusion tensor imaging and functional MRI) to inform the estimation model 17 . An older appearing brain, which is related to advanced physiological and cognitive ageing and mortality 17 , has been found to be an imaging-based hallmark across several brain disorders. To our knowledge, only one preprint (n = 254 MS patients) and one abstract (n = 17 MS patients) have reported brain age estimations in MS 15 19 , and both reported older appearing brains in patients with MS compared to HC.
Here, combining cross-sectional and sensitive measures of MRI-based regional and global brain morphometry in MS and HC (cross-sectional only), we tested the hypothesis that MS patients have higher estimates of brain age than HC in a cross-sectional design. Next, using longitudinal MRI data in MS patients we tested the hypothesis that brain aging accelerates in MS and that the rate of acceleration is associated with a more severe clinical outcome, investigating the associations between the rate of brain aging, disease-modifying treatment (DMT) and clinical trajectories.
MATERIALS AND METHODS

Participants
We included 76 MS patients recruited at Oslo University Hospital 20 21 . fingolimod, natalizumab or alemtuzumab.
The HC group was recruited through newspaper ads or after a stratified random selection drawn from the Norwegian National Population Registry to two parallel studies 18 23 .
Exclusion criteria included estimated intelligence quotient (IQ) <70, history of neurologic or psychiatric disease and current medication significantly affecting the nervous system 24 .
The project was approved by the local ethics committee and in line with the Declaration of Helsinki. All participants received oral and written information and gave their written informed consent.
MRI acquisition
All MS patients were scanned at up to three time points between January 2012 and August 2017, using the same 1. . Specifically an unbiased withinsubject template space and image was created using robust, inverse consistent registration 27 .
Several processing steps, such as skull stripping, Talairach transforms, atlas registration as well as spherical surface maps and parcellations were then initialized with common information from the within-subject template, increasing reliability and power 
Brain age estimation model
The training set for the brain age estimation included data from 3208 HC >12 years (54 % women, mean age 47.5 (±19.8), age range 12-95) obtained from several publicly available datasets ( Supplementary Fig. 2 ). We trained one "xgboost" machine learning model for each sex to predict brain age derived from a total of 1118 cortical and subcortical brain imaging features 15 31 32 .
Based on a recent implementation 15 , brain age estimations were performed both using global and regional features as input. The brain regions reported were based on lobe labels from Freesurfer 25 . The brain age estimation model was carefully evaluated using 10-fold cross-validation within the training set and showed good performance and generalizability ( Supplementary Fig. 3 , r = 0.91). For all patients and HC, we calculated the brain age gap (BAG, defined as the difference between chronological age and imaging-based brain age).
Using linear regressions, we removed any common variance with age, age 2 and sex to account for confounding factors before submitting the residualized version of BAG to further analyses 33 . When pooling estimates of BAG from the 1.5 T and 3 T scanners, we adjusted BAG for scanner effect on BAG estimates by extracting the scanner coefficient from a linear mixed effects (LME) model for global and all brain regions. When comparing BAG between patients and matched HCs we report the actual adjusted difference in BAG between these two groups.
Statistical analyses
We used R (R Core Team, Vienna, 2018) for statistical analyses. All LME models accounted for age, age 2 , sex and scanner 34 .
We estimated an annualized rate of change in BAG by dividing the total change in BAG by the time interval between the time points. We utilized the longest time interval between time points and excluded MS patients lacking longitudinal data (n = 8). The unit used for brain aging is "change in BAG per year". Here, 0 would indicate that the rate of brain aging corresponds to chronological aging, and positive and negative values correspond to accelerated and decelerated brain aging compared to chronological aging, respectively. For all brain regions we tested for significant change in the rate of brain aging by performing a onesample t-test on BAG with 0 set as test value. To assess brain aging within groups stratified by DMT, we used the coefficients from linear models with the individual slope in BAG as dependent variable and age, age 2 , sex and DMT group as independent variables. We estimated the annual global brain atrophy by comparing estimated total brain volume from the Freesurfer output (BrainSegVolNotVent) between time points.
To assess reliability of brain age across time we computed the intraclass correlation coefficient (ICC) using the R package "irr" (https://CRAN.R-project.org/package=irr).
Figures were made using "ggplot2" 35 and "cowplot" (https://CRAN.Rproject.org/package=cowplot) in R. To control for multiple testing we adjusted the p-values using false discovery rate (FDR) 36 procedures implemented in the R package "p.adjust"
(http://stat.ethz.ch/R-manual/R-devel/library/stats/html/p.adjust.html). The linear mixed effect models were performed using the R package "nlme" (https://CRAN.Rproject.org/package=nlme).
Data availability
The data are not publicly available due to local restrictions, since they contain information that may compromise the privacy of research participants. The code needed to reproduce our results is available from the authors upon request. 
RESULTS
Participant demographics and characteristics
Disease modifying treatment
None (%) 17 (22) 22 (29) 19 (31) First line (%) 49 (65) 36 (48) 23 (37) Second line (%) 10 (13) 17 (23) 20 ( 
Cross-sectional case-control analyses (3 T)
At time point 3 we found significantly higher BAG for the MS cohort compared to matched HC for all brain regions except the temporal region ( Fig. 1 ; Table 2 Table 2 and   Supplementary table 3) .
We found a significant annual increase in global BAG of 0.41 (±1.23) years (p = 0.008) in patients with MS ( Fig. 3 ; Supplementary Table 4 and 5). None of the regional measures showed significantly increased annual change in BAG (Supplementary Table 5 ).
We found no significant difference in BAG between the raw and the lesion filled MRI Table 2 . Differences in brain age gap between the multiple sclerosis patients and healthy controls (n = 235). 
T MRI 3 T MRI
0.72
Brain age gap (BAG) estimations are residualized for age, age 2 , sex and scanner. Effect sizes were calculated using Cohen's D estimates.
Significant differences in brain age gap are highlighted with bold (p<0.05). The two groups are matched according to age and sex. Table 4 Fig. 7 ). -0.07 0.57
Associations between global brain age and clinical outcomes
Significant associations are highlighted with bold (p<0.05). Associations which were still significant after adjusting for false discovery rate are underlined. Cor. = correlation; EDSS = expanded disability status scale; MSSS = multiple sclerosis severity score; 9HPT = nine hole peg test; DMT = disease-modifying therapies; WMLL = white matter lesion load.
DISCUSSION
Here, by using advanced cross-sectional and longitudinal MRI-based neuroimaging data as basis for brain age estimation based on machine learning, we tested the hypotheses that patients with MS on average show higher brain age than HC, and that the rate of brain aging is affected by treatment. We found an accelerated brain aging in MS patients compared to controls by cross-sectional and longitudinal brain scans and suggested that increased rates of longitudinal brain aging are associated with higher rates of brain atrophy and increasing WMLL.
We report that MS patients on average had 4. with previously shown lesion probability maps in MS 4 37 .
In our longitudinal patient sample, the annual rate of brain aging for global BAG exceeded that of chronological aging by 0.41 years per year (p = 0.008), which may partly be explained by chronic inflammatory processes that drive neurodegeneration in MS 3 . The association between BAG and brain aging, brain volume and brain atrophy were expected since our estimation model was based on regional and global structural MRI features.
Of notice, brain age estimation takes into account subtle and regional changes that are not included in the global brain atrophy measure. The associations between BAG and brain aging, brain atrophy, brain volume, WMLL and change in WMLL showed significant and regional differences. The associations between change in WMLLs and brain aging were significant for occipital, temporal and parietal brain regions in addition to global BAG (Supplementary Table 9 ). This shows that regional brain age estimation can capture regional specificity of MS pathology, which is in line with the observations that MS lesions show regional affinity 14 15 17 37 .
The significant increase in BAG in the patients receiving no treatment warrants further investigations but is of clinical interest. However, the lack of randomization and group differences in the subgroups calls for caution in the interpretations of this relative small dataset. Table 9 and 10). However, these associations did not survive correction for multiple testing, and further studies are needed to assess the robustness of these observations. Some limitations should be considered when interpreting the results. First, although the cross-sectional case-control comparison and the within-patient longitudinal analysis jointly suggest accelerated brain aging in patients with MS, a longitudinal sample of HCs would have enabled us to directly compare the rate of brain aging between patients and controls. Next, the current brain age model was exclusively based on gross morphometric features. The MS patients were naturalistic, hence any results based on DMT status must be interpreted with care.
In conclusion, using advanced cross-sectional imaging data and machine learning methods we report that patients with MS show evidence of increased brain aging compared to healthy controls. In the longitudinal data we found that MS patients have accelerated brain aging. Higher rates of longitudinally measured brain aging were associated with higher levels of brain atrophy and longitudinal progression of changes in WMLL. These results show that brain age estimation is a promising and intuitive tool for monitoring of the individual disease course in MS and may guide a personalized treatment approach.
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